Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

27/06/2017 ​Barcelona Synchrotron Park’s sustainable brownfield restoration program presented at AquaConSoil 2017 21/06/2017 Catalonia confirms itself as pole of attraction for foreign investments 15/06/2017 Construction of the Natura Bissé’s new world headquarters is well on its way 06/06/2017 ​Walk in the Park: the biodiversity routes await you 31/05/2017 UAB second most innovative university in Spain 24/05/2017 PRUAB: 10 years in strengthening relationships between research and business fabric
16 17 18 19 20 21 22 23 24 25 26